NanOss Bioactive With Autograft and Bone Marrow Aspirate in the Posterolateral Spine
Primary Purpose
Lumbar Spinal Stenosis Secondary to Other Disease
Status
Withdrawn
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
nanOSS
Autograft
Sponsored by
About this trial
This is an interventional treatment trial for Lumbar Spinal Stenosis Secondary to Other Disease focused on measuring Lumbar, fusion
Eligibility Criteria
Inclusion Criteria:
- Is at least 21 years of age and skeletally mature.
- Must have cervical disc disease (defined as neck pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies) at one level in the cervical spine between C3 to T1.
- Must have completed a minimum of six weeks of unsuccessful conservative, non-operative care or has the presence of progressive symptoms or signs of nerve root/spinal cord compression in the face of conservative treatment.
- Has pre-operative objective evidence of primary diagnosis confirmed by appropriate imaging studies (Anteroposterior/Lateral/Flexion/Extension X-rays & a recent MRI).
- Is willing and able to comply with all clinical investigation visits and procedures including screening treatment procedures, post-operative management, the follow-up schedule and completion of forms or questionnaires.
- Is able to understand and sign the patient information sheet/informed consent form.
Exclusion Criteria:
- Requires fusion at more than one level.
- Has had prior fusion at the level to be treated.
- Has a metabolic or systemic bone disorder.
- Has a disease that significantly inhibits bone healing (i.e., severe osteoporosis, osteomalacia, Paget's disease).
- Has a systemic or local infection (active or latent).
- Has acute or chronic infections in the surgical area (i.e., soft tissue infections; inflammatory, bacterial bone disorders, osteomyelitis).
- Chronic use of steroids, other than episodic use or inhaled corticosteroids.
- Has any significant general illness (i.e., HIV, active metastatic cancer of any type, uncontrolled diabetes Type I, dialysis dependent renal failure, symptomatic liver disease).
- Has a mental or physical condition that would limit the ability to comply with study requirements or would preclude accurate evaluation.
- Is immunocompromised or being treated with immunosuppressive agents (including chemotherapy or radiation treatment).
- Has documented allergies to hydroxyapatite or porcine collagen, PEEK, titanium, titanium alloy or tantalum.
- Is currently pregnant, or interested in becoming pregnant during the clinical investigation follow-up.
- Is a smoker.
- Is non-English speaking.
- Requires the use of a bone-growth stimulator.
- Is a prisoner.
- Is currently involved in another drug or device clinical investigation that may confound the clinical trial investigation
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Autograft bone
nanOss with bone marrow aspirate
Arm Description
Outcomes
Primary Outcome Measures
Fusion at 12 months postoperatively.
Secondary Outcome Measures
Full Information
NCT ID
NCT02005341
First Posted
December 3, 2013
Last Updated
January 2, 2017
Sponsor
Pioneer Surgical Technology, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT02005341
Brief Title
NanOss Bioactive With Autograft and Bone Marrow Aspirate in the Posterolateral Spine
Official Title
A Prospective, Nonrandomized Study to Assess Lumbar Fusion With Instrumented Posterolateral Gutter Fusions Using NanOss Bioactive
Study Type
Interventional
2. Study Status
Record Verification Date
January 2017
Overall Recruitment Status
Withdrawn
Why Stopped
A change in research priorities after a merger
Study Start Date
October 2011 (undefined)
Primary Completion Date
September 2014 (Anticipated)
Study Completion Date
September 2014 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Pioneer Surgical Technology, Inc.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to assess lumbar fusion using nanOss Bioactive bone void filler
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lumbar Spinal Stenosis Secondary to Other Disease
Keywords
Lumbar, fusion
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Autograft bone
Arm Type
Active Comparator
Arm Title
nanOss with bone marrow aspirate
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
nanOSS
Intervention Type
Device
Intervention Name(s)
Autograft
Primary Outcome Measure Information:
Title
Fusion at 12 months postoperatively.
Time Frame
12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Is at least 21 years of age and skeletally mature.
Must have cervical disc disease (defined as neck pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies) at one level in the cervical spine between C3 to T1.
Must have completed a minimum of six weeks of unsuccessful conservative, non-operative care or has the presence of progressive symptoms or signs of nerve root/spinal cord compression in the face of conservative treatment.
Has pre-operative objective evidence of primary diagnosis confirmed by appropriate imaging studies (Anteroposterior/Lateral/Flexion/Extension X-rays & a recent MRI).
Is willing and able to comply with all clinical investigation visits and procedures including screening treatment procedures, post-operative management, the follow-up schedule and completion of forms or questionnaires.
Is able to understand and sign the patient information sheet/informed consent form.
Exclusion Criteria:
Requires fusion at more than one level.
Has had prior fusion at the level to be treated.
Has a metabolic or systemic bone disorder.
Has a disease that significantly inhibits bone healing (i.e., severe osteoporosis, osteomalacia, Paget's disease).
Has a systemic or local infection (active or latent).
Has acute or chronic infections in the surgical area (i.e., soft tissue infections; inflammatory, bacterial bone disorders, osteomyelitis).
Chronic use of steroids, other than episodic use or inhaled corticosteroids.
Has any significant general illness (i.e., HIV, active metastatic cancer of any type, uncontrolled diabetes Type I, dialysis dependent renal failure, symptomatic liver disease).
Has a mental or physical condition that would limit the ability to comply with study requirements or would preclude accurate evaluation.
Is immunocompromised or being treated with immunosuppressive agents (including chemotherapy or radiation treatment).
Has documented allergies to hydroxyapatite or porcine collagen, PEEK, titanium, titanium alloy or tantalum.
Is currently pregnant, or interested in becoming pregnant during the clinical investigation follow-up.
Is a smoker.
Is non-English speaking.
Requires the use of a bone-growth stimulator.
Is a prisoner.
Is currently involved in another drug or device clinical investigation that may confound the clinical trial investigation
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
NanOss Bioactive With Autograft and Bone Marrow Aspirate in the Posterolateral Spine
We'll reach out to this number within 24 hrs